APEIRON to present preclinical APN401 data at the 2019 ESMO Congress
Vienna, Austria, 25 September 2019: APEIRON Biologics AG, a biotechnology company developing breakthrough cancer immunotherapies with an approved product on the market, announced today that it will present its development program and data from ongoing preclinical studies of APN401.
European Society for Medical Oncology (ESMO) Congress
27 Sept - 1 Oct 2019 in Barcelona, Spain
Poster: 1231P - Master Checkpoint Cbl-b Inhibition: Anti-tumor Efficacy in a Murine Colorectal Cancer Model Following siRNA-based Cell Therapy
Authors: K. Thell, M. Urban, J. Harrauer, I Haslinger, M Kuttke, JS Brunner, A Vogel, G Schabbauer, J Penninger, A Gaweco
In: Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253
Date: 30 September 2019
Time: Poster Display Session 3, 12pm-1pm
Room: Poster Area Hall 4
About APEIRON Biologics AG
APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies. APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients and out-licensed global, exclusive rights to this product to EUSA Pharma Ltd. APEIRON now leverages its proprietary master checkpoint blockade mechanism to enable the human body’s natural defense mechanisms to fight tumors. APEIRON’s lead clinical program APN401 is a first-in-class autologous cellular therapy to enhance immune reactivity via an intracellular immune master checkpoint, Cbl-b. APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. APEIRON’s development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
For further information please contact:
Media and Investor Relations
MC Services AG
T +49 89 210 228 0